InnovAge (INNV)
Market Price (5/23/2026): $7.185 | Market Cap: $975.0 MilSector: Health Care | Industry: Health Care Facilities
InnovAge (INNV)
Market Price (5/23/2026): $7.185Market Cap: $975.0 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease. Themes include Geriatric Care. | Weak multi-year price returns3Y Excs Rtn is -67% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.5 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -0.5% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.3% Key risksINNV key risks include [1] a documented history of regulatory sanctions for compliance failures, Show more. |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease. Themes include Geriatric Care. |
| Weak multi-year price returns3Y Excs Rtn is -67% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.5 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -0.5% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.3% |
| Key risksINNV key risks include [1] a documented history of regulatory sanctions for compliance failures, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. InnovAge experienced a significant improvement in its financial performance during the fiscal second quarter ended December 31, 2025, reported on February 3, 2026. The company reported total revenues of $239.7 million, a 14.7% increase compared to the prior-year quarter. Crucially, InnovAge achieved a net income of $11.8 million, a notable turnaround from a net loss of $13.5 million in Q2 Fiscal Year 2025. Adjusted EBITDA also saw a substantial rise to $22.2 million from $5.9 million in the same period, reaching a 9.2% margin and meeting its intermediate-term target. This strong performance led the company to raise its full-year fiscal 2026 guidance, projecting total revenue between $925 million and $950 million and Adjusted EBITDA between $70 million and $75 million.
2. The company demonstrated continued operational momentum with strong revenue growth and a further increase in its full-year fiscal 2026 guidance during the fiscal third quarter ended March 31, 2026, reported on May 5, 2026. InnovAge posted total revenues of $251.9 million, an increase of approximately 15.5% year-over-year. Adjusted EBITDA rose to $30.5 million, marking an increase of $19.7 million compared to Q3 Fiscal Year 2025. The center-level contribution margin also improved to 24.2%. Reflecting this sustained positive trend, the company again raised its full-year fiscal 2026 guidance, now expecting revenue between $950 million and $975 million and Adjusted EBITDA between $85 million and $90 million. This positive outlook was a core reason for investor confidence, even as the company reported a wider net loss of $29.9 million for the quarter, largely attributed to higher legal and litigation expenses.
Show more
Stock Movement Drivers
Fundamental Drivers
The 29.7% change in INNV stock from 1/31/2026 to 5/22/2026 was primarily driven by a 21.0% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5222026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.55 | 7.20 | 29.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 885 | 949 | 7.3% |
| P/S Multiple | 0.9 | 1.0 | 21.0% |
| Shares Outstanding (Mil) | 136 | 136 | -0.1% |
| Cumulative Contribution | 29.7% |
Market Drivers
1/31/2026 to 5/22/2026| Return | Correlation | |
|---|---|---|
| INNV | 29.7% | |
| Market (SPY) | 8.1% | 19.1% |
| Sector (XLV) | -2.7% | 36.2% |
Fundamental Drivers
The 60.4% change in INNV stock from 10/31/2025 to 5/22/2026 was primarily driven by a 44.8% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5222026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.49 | 7.20 | 60.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 854 | 949 | 11.2% |
| P/S Multiple | 0.7 | 1.0 | 44.8% |
| Shares Outstanding (Mil) | 135 | 136 | -0.4% |
| Cumulative Contribution | 60.4% |
Market Drivers
10/31/2025 to 5/22/2026| Return | Correlation | |
|---|---|---|
| INNV | 60.4% | |
| Market (SPY) | 9.9% | 5.5% |
| Sector (XLV) | 4.8% | 28.9% |
Fundamental Drivers
The 130.0% change in INNV stock from 4/30/2025 to 5/22/2026 was primarily driven by a 95.9% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5222026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.13 | 7.20 | 130.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 807 | 949 | 17.7% |
| P/S Multiple | 0.5 | 1.0 | 95.9% |
| Shares Outstanding (Mil) | 135 | 136 | -0.2% |
| Cumulative Contribution | 130.0% |
Market Drivers
4/30/2025 to 5/22/2026| Return | Correlation | |
|---|---|---|
| INNV | 130.0% | |
| Market (SPY) | 36.0% | 22.4% |
| Sector (XLV) | 8.6% | 29.4% |
Fundamental Drivers
The 17.8% change in INNV stock from 4/30/2023 to 5/22/2026 was primarily driven by a 37.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5222026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.11 | 7.20 | 17.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 689 | 949 | 37.8% |
| P/S Multiple | 1.2 | 1.0 | -14.4% |
| Shares Outstanding (Mil) | 136 | 136 | -0.1% |
| Cumulative Contribution | 17.8% |
Market Drivers
4/30/2023 to 5/22/2026| Return | Correlation | |
|---|---|---|
| INNV | 17.8% | |
| Market (SPY) | 86.3% | 24.1% |
| Sector (XLV) | 18.0% | 26.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| INNV Return | -79% | 44% | -16% | -34% | 32% | 42% | -70% |
| Peers Return | 39% | 2% | 18% | 13% | 21% | 2% | 134% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| INNV Win Rate | 30% | 67% | 67% | 33% | 42% | 60% | |
| Peers Win Rate | 63% | 53% | 57% | 53% | 62% | 32% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| INNV Max Drawdown | - | -48% | -35% | -44% | -34% | -33% | |
| Peers Max Drawdown | -22% | -37% | -25% | -31% | -30% | -26% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ACHC, HCA, THC, ENSG, UHS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/22/2026 (YTD)
How Low Can It Go
| Event | INNV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -21.6% | -18.8% |
| % Gain to Breakeven | 27.6% | 23.1% |
| Time to Breakeven | 30 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -28.6% | -9.5% |
| % Gain to Breakeven | 40.0% | 10.5% |
| Time to Breakeven | 826 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -25.2% | -6.7% |
| % Gain to Breakeven | 33.6% | 7.1% |
| Time to Breakeven | 42 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -30.1% | -24.5% |
| % Gain to Breakeven | 43.1% | 32.4% |
| Time to Breakeven | 9 days | 427 days |
In The Past
InnovAge's stock fell -21.6% during the 2025 US Tariff Shock. Such a loss loss requires a 27.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | INNV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -21.6% | -18.8% |
| % Gain to Breakeven | 27.6% | 23.1% |
| Time to Breakeven | 30 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -28.6% | -9.5% |
| % Gain to Breakeven | 40.0% | 10.5% |
| Time to Breakeven | 826 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -25.2% | -6.7% |
| % Gain to Breakeven | 33.6% | 7.1% |
| Time to Breakeven | 42 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -30.1% | -24.5% |
| % Gain to Breakeven | 43.1% | 32.4% |
| Time to Breakeven | 9 days | 427 days |
In The Past
InnovAge's stock fell -21.6% during the 2025 US Tariff Shock. Such a loss loss requires a 27.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About InnovAge (INNV)
AI Analysis | Feedback
Kaiser Permanente for seniors, but focused on keeping them independent in their homes and communities.
A 'one-stop-shop' like Sam's Club or Costco, but for all the medical, social, and daily living needs of seniors who want to live independently at home.
AI Analysis | Feedback
- Program of All-Inclusive Care for the Elderly (PACE): An integrated healthcare model that provides comprehensive medical and ancillary services to seniors allowing them to live independently.
- In-Home Care Services: Direct care provided in participants' homes, encompassing skilled nursing, unskilled assistance, and personal care.
- In-Center Services: A variety of medical, therapeutic, nutritional, and social services delivered at dedicated PACE centers.
- Transportation Services: Coordinated transportation for participants to attend appointments at PACE centers and other third-party medical facilities.
- Care Management: Professional oversight and coordination of all aspects of a participant's individualized care plan.
AI Analysis | Feedback
InnovAge (INNV) primarily sells its services directly to individuals. The company manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in their homes and communities through the Program of All-Inclusive Care for the Elderly (PACE) approach.
The categories of customers it serves are:
- Seniors and Elderly Individuals: The company's core mission is to serve older adults who require comprehensive care and support to maintain their independence and live in their homes and communities.
- Participants in the Program of All-Inclusive Care for the Elderly (PACE): InnovAge's customer base consists of individuals enrolled in the PACE program. These participants are typically 55 years or older, certified by their state to need nursing home-level care, and able to live safely in the community with PACE services. The company serves approximately 6,850 PACE participants.
AI Analysis | Feedback
nullAI Analysis | Feedback
Patrick Blair, Chief Executive Officer
Patrick Blair was appointed CEO of InnovAge in January 2022. He has a tenure of over four years with the company.
Ben Adams, Chief Financial Officer
Ben Adams joined InnovAge as Chief Financial Officer in July 2023. He previously served as CFO of Kepro, a physician-led, technology-enabled company, and RxSense, LLC. Earlier in his career, Adams spent over two decades as a senior healthcare investment banker.
Christine Bent, Chief Operations Officer
Christine Bent was named Chief Operations Officer of InnovAge in March 2023. Prior to joining InnovAge, she was Senior Vice President and COO at Prime Therapeutics LLC, a privately held pharmacy benefit manager. She also held clinical and operations leadership roles at Allina Health for 12 years, and leadership positions at Atrius Health and Partners Community Healthcare.
Paul Taheri, MD, MBA, Chief Medical Officer
Dr. Paul Taheri was appointed Chief Medical Officer of InnovAge in November 2025. He previously served as Clinical Quality Advisor to Welsh, Carson, Anderson & Stowe (WCAS), a private equity firm that is a major shareholder in InnovAge. Dr. Taheri's prior experience includes roles as CEO and Deputy Dean for Clinical Affairs at Yale School of Medicine, and President and CEO of the University of Vermont Medical Group.
Nicole D'Amato, Chief Legal Officer & Corporate Secretary
Nicole D'Amato has served as InnovAge's Chief Legal Officer and Corporate Secretary since July 2021. Before InnovAge, she was Senior Vice President at MacAndrews & Forbes, a company that owned a majority stake in Revlon, Inc. and was a major shareholder of Scientific Games, among other private companies. She also held senior legal roles at DIAGEO North America, Inc. and Samsonite, LLC, where she was involved in Samsonite's initial public offering on the Hong Kong Stock Exchange.
AI Analysis | Feedback
```htmlKey Risks to InnovAge (INNV)
- Regulatory Scrutiny and Dependence on Government Payors: InnovAge operates under the Program of All-Inclusive Care for the Elderly (PACE) model, making its revenue highly dependent on government payors like Medicare and Medicaid. This exposes the company to significant regulatory risks, including audits, policy changes, and potential sanctions for non-compliance. InnovAge has previously faced enrollment suspensions and citations for care deficiencies from the Centers for Medicare & Medicaid Services (CMS) and state regulators, directly impacting its ability to enroll new participants and grow its business.
- Cost Management Challenges within a Capitated Model: As a PACE provider, InnovAge assumes 100% of the healthcare costs for its participants under a capitated payment model. While this model aims to incentivize preventive care and cost reduction, there is a substantial risk that the cost of providing comprehensive services, especially to its high-acuity population with an average of ten chronic conditions, could exceed the fixed compensation received. Challenges in managing these costs effectively, coupled with rising care expenses and losses from new centers, could hinder the company's path to consistent profitability.
- Staffing Shortages and Maintaining Quality of Care: InnovAge faces challenges related to workforce shortages in the healthcare sector, particularly for geriatric and primary care. Current and former employees have cited understaffing, high caseloads, and organizational dysfunction leading to delayed or inadequate care for participants. Such issues directly impact the quality of care provided, patient satisfaction, and can lead to regulatory actions and reputational damage, all of which are critical for the long-term success of a healthcare service provider.
AI Analysis | Feedback
The increasing trend among Medicare Advantage (MA) plans to offer comprehensive supplemental benefits, including in-home support, transportation, meal delivery, and enhanced care coordination, which directly overlap with and provide an alternative to the all-inclusive services offered by the Program of All-Inclusive Care for the Elderly (PACE) model.
AI Analysis | Feedback
The total addressable market for InnovAge's main product and service, the Program of All-Inclusive Care for the Elderly (PACE), is estimated to be $260 billion in the United States.
This market size is based on an estimated 2.3 million PACE-eligible individuals in the U.S. as of 2023. InnovAge targets frail, high-cost seniors who are dually eligible for Medicare and Medicaid and meet nursing home eligibility criteria. Currently, only a small fraction of these eligible individuals are enrolled in PACE programs, with approximately 77,000 participants as of June 2024.
AI Analysis | Feedback
InnovAge Holding Corp. (INNV) is expected to drive future revenue growth over the next two to three years through several key strategies:
- Participant Growth (Census Growth): InnovAge consistently emphasizes increasing its participant base within its Program of All-Inclusive Care for the Elderly (PACE). The company reported serving approximately 8,010 participants across 20 centers as of December 31, 2025, marking a 7.1% growth compared to the second quarter of fiscal year 2025. InnovAge's fiscal year 2026 guidance projects an ending census of 7,900 to 8,100 participants.
- Increased Capitation Rates: A significant portion of InnovAge's revenue is derived from capitation rates, which include annual adjustments from Medicaid and Medicare. Increases in these capitation rates directly contribute to revenue growth.
- Expansion of De Novo Centers: InnovAge is actively expanding its footprint by opening new "de novo" centers, such as those in Florida. While these new centers initially incur losses during their ramp-up phase, they are anticipated to become substantial contributors to revenue as they mature and increase participant enrollment.
- Successful Medicaid Reinstatements: The company has seen revenue growth driven by its success in reinstating participants who had previously lost Medicaid coverage. This initiative directly contributes to census growth and, consequently, revenue.
- Operational Efficiencies and Revenue Integrity: InnovAge is improving its revenue through enhanced revenue integrity processes, including a reduction in revenue write-offs and a strengthened Medicaid eligibility tracking system. These operational improvements ensure the company effectively captures the revenue it is entitled to, thereby contributing to overall revenue growth and profitability.
AI Analysis | Feedback
Share Repurchases
- InnovAge reported a repurchase of equity securities totaling approximately $5.912 million in a period within fiscal year 2025.
Share Issuance
- InnovAge completed its Initial Public Offering (IPO) in March 2021, issuing 16,666,667 shares of common stock at a price of $21.00 per share, raising approximately $350.07 million in gross proceeds.
- Including a partial exercise of the underwriters' option to purchase additional shares, the IPO ultimately involved 18,995,901 shares, generating approximately $399 million in gross proceeds.
Inbound Investments
- Prior to its IPO, InnovAge was a portfolio company backed by private equity firms Apax Partners LLP and Welsh, Carson, Anderson and Stowe LP.
Capital Expenditures
- For the second quarter of fiscal year 2026 (ended December 31, 2025), InnovAge incurred $2.4 million in capital expenditures.
- The company anticipates requiring significant capital expenditures to grow and evolve its operational and financial operations, including ensuring personnel licensing and training.
- InnovAge's investments aim to improve health outcomes and reduce medical costs for participants, with long-term plans to reinvest savings back into the InnovAge Platform.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Is 28.2% Fall In InnovAge (INNV) Stock A Buying Opportunity? | 04/03/2026 | |
| InnovAge Stock (+12%): CMS Retroactive Payments for PACE Sector Drive Rally | 03/05/2026 | |
| InnovAge Earnings Notes | 12/16/2025 | |
| With InnovAge Stock Surging, Have You Considered The Downside? | 10/17/2025 | |
| InnovAge Stock Jumps 11% In A Week, Time To Buy The Stock? | 08/09/2025 | |
| InnovAge (INNV) Operating Income Comparison | 08/08/2025 | |
| InnovAge (INNV) Operating Cash Flow Comparison | 08/08/2025 | |
| InnovAge (INNV) Net Income Comparison | 08/08/2025 | |
| InnovAge (INNV) EBITDA Comparison | 08/08/2025 | |
| InnovAge (INNV) Debt Comparison | 08/08/2025 | |
| ARTICLES | ||
| Time To Buy The Dip In InnovAge Stock? | 05/23/2026 | |
| Down 28%, Is InnovAge Stock a Buy Now? | 04/03/2026 |
Trade Ideas
Select ideas related to INNV.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 03312021 | INNV | InnovAge | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | -75.1% | -75.1% | -84.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 164.87 |
| Mkt Cap | 9.8 |
| Rev LTM | 11,517 |
| Op Inc LTM | 1,245 |
| FCF LTM | 550 |
| FCF 3Y Avg | 522 |
| CFO LTM | 1,249 |
| CFO 3Y Avg | 1,108 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.6% |
| Rev Chg 3Y Avg | 8.6% |
| Rev Chg Q | 10.2% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Inc Chg LTM | 17.9% |
| Op Inc Chg 3Y Avg | 17.2% |
| Op Mgn LTM | 11.6% |
| Op Mgn 3Y Avg | 12.6% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 11.0% |
| CFO/Rev 3Y Avg | 10.3% |
| FCF/Rev LTM | 4.7% |
| FCF/Rev 3Y Avg | 4.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 9.8 |
| P/S | 0.9 |
| P/Op Inc | 5.0 |
| P/EBIT | 4.1 |
| P/E | 7.6 |
| P/CFO | 9.2 |
| Total Yield | 6.1% |
| Dividend Yield | 0.1% |
| FCF Yield 3Y Avg | 4.4% |
| D/E | 0.5 |
| Net D/E | 0.5 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -10.9% |
| 3M Rtn | -21.4% |
| 6M Rtn | -8.2% |
| 12M Rtn | 6.5% |
| 3Y Rtn | 38.3% |
| 1M Excs Rtn | -16.2% |
| 3M Excs Rtn | -32.0% |
| 6M Excs Rtn | -19.6% |
| 12M Excs Rtn | -22.6% |
| 3Y Excs Rtn | -47.0% |
Price Behavior
| Market Price | $7.20 | |
| Market Cap ($ Bil) | 1.0 | |
| First Trading Date | 03/04/2021 | |
| Distance from 52W High | -32.1% | |
| 50 Days | 200 Days | |
| DMA Price | $7.93 | $6.20 |
| DMA Trend | up | down |
| Distance from DMA | -9.2% | 16.2% |
| 3M | 1YR | |
| Volatility | 57.8% | 82.9% |
| Downside Capture | 189.98 | 90.34 |
| Upside Capture | 87.68 | 131.79 |
| Correlation (SPY) | 34.5% | 20.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.61 | 1.87 | 1.35 | 0.44 | 1.55 | 1.15 |
| Up Beta | 1.24 | 0.98 | 1.83 | 1.32 | 2.14 | 1.37 |
| Down Beta | 0.37 | 1.23 | 1.55 | -0.06 | 1.22 | 0.79 |
| Up Capture | 97% | 194% | 222% | 102% | 278% | 143% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 12 | 20 | 32 | 63 | 128 | 361 |
| Down Capture | 766% | 272% | 44% | -32% | 100% | 106% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 22 | 30 | 57 | 113 | 364 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INNV | |
|---|---|---|---|---|
| INNV | 75.2% | 82.9% | 1.02 | - |
| Sector ETF (XLV) | 16.0% | 14.5% | 0.80 | 31.7% |
| Equity (SPY) | 29.5% | 12.0% | 1.86 | 20.4% |
| Gold (GLD) | 35.5% | 26.8% | 1.11 | 10.6% |
| Commodities (DBC) | 42.9% | 18.7% | 1.77 | -1.9% |
| Real Estate (VNQ) | 15.2% | 13.1% | 0.82 | 32.5% |
| Bitcoin (BTCUSD) | -29.5% | 41.7% | -0.73 | 10.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INNV | |
|---|---|---|---|---|
| INNV | -19.2% | 74.3% | 0.04 | - |
| Sector ETF (XLV) | 5.7% | 14.7% | 0.21 | 25.4% |
| Equity (SPY) | 14.0% | 17.0% | 0.64 | 27.1% |
| Gold (GLD) | 18.8% | 18.0% | 0.85 | 8.4% |
| Commodities (DBC) | 10.4% | 19.4% | 0.42 | 3.1% |
| Real Estate (VNQ) | 3.8% | 18.8% | 0.10 | 28.9% |
| Bitcoin (BTCUSD) | 12.2% | 55.3% | 0.42 | 13.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INNV | |
|---|---|---|---|---|
| INNV | -11.5% | 73.4% | 0.00 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 25.3% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 27.0% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 8.4% |
| Commodities (DBC) | 7.8% | 17.9% | 0.35 | 3.2% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 28.3% |
| Bitcoin (BTCUSD) | 67.2% | 66.9% | 1.06 | 13.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/5/2026 | 2.0% | -5.2% | |
| 2/3/2026 | 37.5% | 47.9% | 68.4% |
| 9/9/2025 | -2.8% | 21.3% | 36.8% |
| 5/6/2025 | 14.4% | 38.9% | 39.3% |
| 2/4/2025 | -9.1% | -8.9% | -6.8% |
| 9/10/2024 | -6.5% | -3.7% | -8.3% |
| 5/7/2024 | 0.0% | -5.6% | 13.4% |
| 2/6/2024 | -3.9% | -3.0% | -8.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 8 | 7 |
| # Negative | 8 | 8 | 8 |
| Median Positive | 4.1% | 14.7% | 25.0% |
| Median Negative | -6.6% | -7.3% | -9.6% |
| Max Positive | 37.5% | 52.3% | 68.4% |
| Max Negative | -24.9% | -41.8% | -43.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 02/03/2026 | 10-Q |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 09/09/2025 | 10-K |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/04/2025 | 10-Q |
| 09/30/2024 | 11/05/2024 | 10-Q |
| 06/30/2024 | 09/10/2024 | 10-K |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/06/2024 | 10-Q |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 09/12/2023 | 10-K |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/07/2023 | 10-Q |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 09/13/2022 | 10-K |
Recent Forward Guidance [BETA]
Latest: Q3 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Census | 7,900 | 8,000 | 8,100 | 0 | Affirmed | Guidance: 8,000 for 2026 | |
| 2026 Total Member Months | 92,900 | 94,300 | 95,700 | 0 | Affirmed | Guidance: 94,300 for 2026 | |
| 2026 Revenue | 950.00 Mil | 962.50 Mil | 975.00 Mil | 2.7% | Raised | Guidance: 937.50 Mil for 2026 | |
| 2026 Adjusted EBITDA | 85.00 Mil | 87.50 Mil | 90.00 Mil | 20.7% | Raised | Guidance: 72.50 Mil for 2026 | |
Prior: Q2 2026 Earnings Reported 2/3/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Census | 7,900 | 8,000 | 8,100 | 0 | Affirmed | Guidance: 8,000 for 2026 | |
| 2026 Total Member Months | 92,900 | 94,300 | 95,700 | 1.4% | Raised | Guidance: 93,000 for 2026 | |
| 2026 Revenue | 925.00 Mil | 937.50 Mil | 950.00 Mil | 1.4% | Raised | Guidance: 925.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | 70.00 Mil | 72.50 Mil | 75.00 Mil | 19.8% | Raised | Guidance: 60.50 Mil for 2026 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Scarbrough, Michael Anthony | President and COO | Direct | Sell | 11172025 | 4.90 | 33,000 | 161,700 | 586,123 | Form |
| 2 | Zoretic, Richard C | Direct | Buy | 5302025 | 4.08 | 8,450 | 34,476 | 279,456 | Form | |
| 3 | Zoretic, Richard C | Direct | Buy | 5302025 | 4.04 | 14,265 | 57,631 | 242,578 | Form | |
| 4 | Zoretic, Richard C | Direct | Buy | 5302025 | 4.06 | 20,000 | 81,200 | 185,863 | Form | |
| 5 | Zoretic, Richard C | Direct | Buy | 5232025 | 3.93 | 1,198 | 4,708 | 101,311 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.